


PHARMACEUTICAL 2022

DURECT CORP Rank 253 of 475







PHARMACEUTICAL 2022

DURECT CORP Rank 253 of 475



The relative strengths and weaknesses of DURECT CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of DURECT CORP compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 39% points. The greatest weakness of DURECT CORP is the variable Research and Development, reducing the Economic Capital Ratio by 83% points.

The company's Economic Capital Ratio, given in the ranking table, is -112%, being 164% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	81,737
Cost of Goods Sold	1,955
Intangible Assets	6,169
Liabilities, Current	10,056
Liabilities, Non-Current	0
Other Assets	3,857
Other Compr. Net Income	-5.0
Other Expenses	0
Other Liabilities	0
Other Net Income	-1,992
Property and Equipment	227
Research and Development	31,846
Revenues	13,977
Selling, General and Administrative Expense	14,449

Output Variable	Value in 1000 USD
Assets	91,990
Liabilities	10,056
Expenses	48,250
Stockholders Equity	81,934
Net Income	-36,265
Comprehensive Net Income	-36,268
Economic Capital Ratio	-112%

